Freestone Grove Partners LP
Position in CAI — Caris Life Sciences, Inc.
CIK 2007591
San Francisco, CA
Position in CAI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$65,132
+$65,025 QoQ
Shares Held
3,655
+60816.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#183
of 246 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CAI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Freestone Grove Partners LP holds $121,397,798 across 51 Biotechnology names. CAI ranks #41 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
339,967 | $26,955,983 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
364,194 | $20,839,180 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
64,813 | $12,138,178 | |
| 4 | CYTK |
Cytokinetics Inc
|
114,824 | $9,781,856 | |
| 5 | CELC |
Celcuity Inc.
|
67,907 | $7,104,430 | |
| 6 | MPLT |
MapLight Therapeutics, Inc.
|
168,912 | $6,053,806 | |
| 7 | ANL |
Adlai Nortye Ltd.
|
397,446 | $4,570,629 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
68,389 | $4,304,403 |
All Filings in CAI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $65,132 | 3,655 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $107 | 6 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $7,604,517 | 251,389 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,336,000 | 50,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||